Navigation Links
In a World First, Asda Announces 'Not for Profit' Price on All Cancer Treatment Drugs
Date:5/20/2010

The annual spend per cancer patient across the 152 PCTs in England can vary by as much as 286 per cent. This 'post code lottery' impacts patients as it determines the cancer treatment people are eligible for on the NHS.

Variations on cancer drug availability on the NHS

There are significant variations in the cancer drugs which are available on the NHS within each PCT. Drugs such as Iressa and Afinitor, which treat lung cancer and kidney cancer, are only available with a private prescription. This means that should a patient require either drug, they have no other option but to pay for it under a private prescription.

John Evans, Superintendent Pharmacist at Asda, comments:

"The crippling cost of paying privately for cancer treatment has forced many people to spend their savings or even re-mortgage their house to pay for these essential drugs.

"We are the first retailer to recognise this injustice and to do something about it and we are calling on other retailers to follow our lead. It's a small step in the right direction but, our permanent 'not for profit' price on cancer treatment drugs makes them more accessible and can save people hundreds if not thousands of pounds."

Asda's new CEO Andy Clarke, who lost his own parents to cancer, supported the move to make these vital drugs available at the lowest possible price.

"Saving people money so they can live better is viewed by many as just the marketing slogan of our parent company, Walmart.

"However, when you see what we can achieve in areas like cancer and IVF treatments to reduce prices, the reality of that mission statement
'/>"/>

SOURCE Walmart
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Still River Systems Announces Production Milestone for the Worlds Smallest High-Energy Proton Therapy Accelerator
2. Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond
3. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
4. Reportlinker Adds The World Anesthesia Drug Market
5. WorldHeart Appoints Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs
6. Eye-Fi Expands Hotspot Access Service Worldwide
7. Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5
8. Cruise West Guests Rave About Inaugural World Voyage
9. New Microplegia Service: Worlds First Low-Potassium, Non-Depolarizing Cardioplegia Available Exclusively from CAPS(R)
10. World TB Day Senate Briefing
11. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  Packaging Coordinators, Inc. (PCI) is ... to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma ... in the United Kingdom and ... and Tokyo , Japan. Penn ... Clinical and Commercial dosage form manufacturing, as well as ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... COLLEGEVILLE, Pa., July 27 ... WYE ), announced the publication in Fertility and Sterility ... showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced ... of vaginal atrophy when compared to placebo. In this study, ...
... , , ENGLEWOOD CLIFFS, ... all regular body washes caused dry skin damage. Now, ... while cleansing with body wash. Current body washes actually damage ... to the loss of critical moisture. Recognizing skin lipids require ...
Cached Medicine Technology:Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 2Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 3Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 4Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 5Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 6Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 2Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 3Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 4
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent ... this nasty condition which occurs most frequently in people between ... to two and half years if not treated. , Adhesive ... good reason: it can render your shoulder so stiff, it's ... you aren't in too much pain to get dressed in ...
(Date:7/30/2014)... (HealthDay News) -- For patients with asthma, just believing ... airway inflammation for at least 24 hours, a new ... but also what you think you smell," study author ... in Philadelphia, said in a Monell news release. ... When we expect that an odor is harmful, our ...
(Date:7/30/2014)... vast majority of kids with autism have abnormal sensory ... children who have trouble processing sensory stimuli, researchers report. ... overly sensitive to sound, sight and touch. They can ... of concentration. Complicating matters, some kids with SPD ... tolerating loud noises, like a vacuum. Others can,t hold ...
(Date:7/30/2014)... months or more as babies have a significantly ... and metabolic diseases, according to research from the ... , "This study shows that birthweight and breastfeeding ... said Molly W. Metzger, PhD, assistant professor at ... study with Thomas W. McDade, PhD, of Northwestern ...
(Date:7/30/2014)... 2014 On July 29, 2014, Freedom ... Institute of Public Health, Gandhinagar released a new report ... II: The Way Forward .” The report was released ... and Practices to Improve Nutrition Security in New Delhi, ... the Green Revolution" and chair of the Coalition ...
Breaking Medicine News(10 mins):Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4
... URAC CEO joins company along with ... Chief Medical Officer, ANNAPOLIS, Md., ... management leaders to head the,growing healthcare consulting and technology company. Senior management ... -- Joel V. Brill, MD, AGAF FASGE FACG CHCQM, Chief Medical ...
... Philadelphia, PA, September 20, 2007 Mark Twain boasted that it ... We now may have the beginnings of understanding why some ... are in treatment for this problem. According to statistics provided ... is the leading preventable cause of death in the United States, ...
... save years in research that aligns patients ... Fla., Sept. 20 The,H. Lee Moffitt ... Azyxxi(R),the Microsoft(R) unified health enterprise platform, to ... programs. Azyxxi will be used,to assimilate large ...
... Calif., Sept. 20 /PRNewswire-FirstCall/-- DURECT Corporation,(Nasdaq: DRRX ... CEO, will,present at the UBS Global Life Sciences ... 1:30 p.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ... presentation will be available by accessing,DURECT,s homepage at ...
... Healthcare Group,Inc. (OTC Bulletin Board: SNVH), today announced that ... notional principal amount of its,6.5% senior convertible promissory notes, ... purchase warrants. This sale was effected as the,initial part ... in the,aggregate notional principal amount of up to $5 ...
... Childrens Hospital of Pittsburgh of UPMC psychiatrist Eva M. Szigethy, ... have been chosen by the director of the National Institutes ... , NIH director Elias A. Zerhouni, MD, announced today that ... in the early stages of their careers, including Dr. Szigethy ...
Cached Medicine News:Health News:Schooner Healthcare Services, LLC Announces New Leadership Team 2Health News:Genetic variation affects smoking cessation treatment 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Children's Hospital of Pittsburgh psychiatrist receives prestigious NIH award 2
With this more compact transducer face, this is the transducer of choice for obstetric imaging in areas with a small acoustic window....
... The 9101-7.5 convex array is designed with ... resolution obtained with this multi-frequency transducer is ... in need of quick and accurate diagnoses. ... versatility you need, and allows you to ...
... The new XL3000 by ... illuminator,featuring the latest in,Cermax Xenon ... optic illumination technology,for integration into ... that require,bright, accurate color illumination.,It ...
... Test System* is a multiplexed, fluorescent, ... multiple assays from a single sample ... a simple and streamlined alternative to ... clinical sensitivity and comparable clinical specificity ...
Medicine Products: